Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Scientific Reports|November 7, 2020
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancerGiandomenico Roviello, Monica Ramello, Martina Catalano, et al.
American Journal of Clinical Oncology|October 24, 2002
Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcomaRoberto Petrioli, Andrea Coratti, Pierpaolo Correale, et al.
Annali Italiani Di Chirurgia|December 5, 2023
Neuroendocrine tumors' patients treated with somatostatin analogue could complicate with emergency cholecystectomyNatale Calomino, Gianmario Edoardo Poto, Ludovico Carbone, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 13, 2021
Signet ring cell percentage in poorly cohesive gastric cancer patients: A potential novel predictor of survivalFranco Roviello, Luigi Marano, Maria Raffaella Ambrosio, et al.
Anti-Cancer Drugs|December 19, 2019
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancerRoberto Petrioli, Edoardo Francini, Sara Cherri, et al.
International Journal of Clinical Oncology|January 18, 2011
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancerFilippo Francini, Alessandra Pascucci, Gianluca Bargagli, et al.
Cancers|April 13, 2024
Posterior and Para-Aortic (D2plus) Lymphadenectomy after Neoadjuvant/Conversion Therapy for Locally Advanced/Oligometastatic Gastric CancerDaniele Marrelli, Stefania Angela Piccioni, Ludovico Carbone, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|July 1, 2025
Impact of HER2 and microsatellite instability status on response to neoadjuvant/conversion therapy and survival in patients with gastric cancerStefania Angela Piccioni, Maurizio Costantini, Roberto Petrioli, et al.
Surgical Oncology|November 1, 2019
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancerRoberto Petrioli, Daniele Marrelli, Franco Roviello, et al.
Frontiers in Oncology|June 20, 2022
The Percentage of Signet Ring Cells Is Inversely Related to Aggressive Behavior and Poor Prognosis in Mixed-Type Gastric CancerLuigi Marano, Maria Raffaella Ambrosio, Luca Resca, et al.
Pageof 11